Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

被引：0
|
作者：
Hart, A. [1 ,2 ]
Martin-Arranz, M. D. [3 ]
Laharie, D. [4 ]
Matsuoka, K. [5 ]
Dhesi, E. [6 ]
Redondo, I. [6 ]
Baygani, S. [6 ]
Zaremba-Pechmann, L. [7 ]
Samaan, K. [6 ]
Navabi, S. [8 ]
机构：
[1] St Marks Hosp, London, England
[2] Imperial Coll, Dept Metab Digest & Reprod, London, England
[3] Hosp La Paz Inst Hlth Res, Dept Gastroenterol, Madrid, Spain
[4] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France
[5] Toho Univ, Div Gastroenterol & Hepatol, Sakura Med Ctr, Dept Internal Med, Sakura, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmBH, Stat, Schriesheim, Germany
[8] United Med Doctors, Gastroenterol Hepatol & Obes Med, Long Beach, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP14
引用
收藏
页码：I27 / I28
页数：2
相关论文
共 50 条
  • [31] Mirikizumab Improves Patient Assessments of Disease Severity and Change in Disease Activity in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Travis, Simon
    Wu, Jianmin
    Sapin, Christophe
    Gibble, Theresa Hunter
    Hibi, Toshifumi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S30 - S31
  • [32] EFFICACY OF INFLIXIMAB AFTER FAILURE OF SUBCUTANEOUS ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A MULTICENTER STUDY
    Streichenberger, Aurelie
    Pariente, Benjamin
    Bozon, Anne
    Arab, Nadia
    Amiot, Aurelien
    Vuitton, Lucine
    Tilmant, Marion
    Nachury, Maria
    Altwegg, Romain
    Delasalle, Thibault
    Gagniere, Charlotte
    Boivineau, Gregoire
    Fumery, Mathurin
    Wils, Pauline
    de Chambrun, Guillaume Pineton
    Hebuterne, Xavier
    Pereira, Bruno
    Bommelaer, Gilles
    Buisson, Anthony
    GASTROENTEROLOGY, 2018, 154 (06) : S834 - S834
  • [33] Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study
    Streichenberger, A.
    Pariente, B.
    Bozon, A.
    Arab, N.
    Amiot, A.
    Vuitton, L.
    Tilmant, M.
    Nachury, M.
    Altwegg, R.
    Delasalle, T.
    Gagniere, C.
    Gregoire, B.
    Fumery, M.
    Wils, P.
    de Chambrun, G. Pineton
    Hebuterne, X.
    Pereira, B.
    Bommelaer, G.
    Buisson, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S291 - S291
  • [34] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S43 - S44
  • [35] Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
    Dignass, Axel
    Danese, Silvio
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Li, Xingyuan
    Morris, Nathan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S558 - S558
  • [36] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [37] Biological Therapy for Ulcerative Colitis: What is after Anti-TNF
    Fiorino, Gionata
    Cesarini, Monica
    Danese, Silvio
    CURRENT DRUG TARGETS, 2011, 12 (10) : 1433 - 1439
  • [38] Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
    Friedrich, Stuart
    Chua, Laiyi
    Adams, David H.
    Crandall, Wallace
    Zhang, Xin Cindy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, : 435 - 447
  • [39] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [40] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
12345